Xiangsheng Zuo1, Yasunori Deguchi2, Weiguo Xu2, Yi Liu2, Haiyan S Li3, Daoyan Wei4, Rui Tian2, Weidong Chen2, Min Xu2, Yaying Yang2, Shen Gao2, Jonathan C Jaoude2, Fuyao Liu2, Sarah P Chrieki2, Micheline J Moussalli5, Mihai Gagea6, Manu M Sebastian7, Xiaofeng Zheng8, Dongfeng Tan5, Russell Broaddus5, Jing Wang8, Nadim J Ajami9, Alton G Swennes10, Stephanie S Watowich3, Imad Shureiqi11. 1. Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: xzuo@mdanderson.org. 2. Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Departments of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Departments of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Departments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Departments of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Departments of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas. 8. Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 9. Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine, Houston, Texas; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas. 10. Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas; Center for Comparative Medicine, Baylor College of Medicine, Houston, Texas. 11. Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: ishureiqi@mdanderson.org.
Abstract
BACKGROUND & AIMS: The peroxisome proliferator-activated receptor delta (PPARD) regulates cell metabolism, proliferation, and inflammation and has been associated with gastric and other cancers. Villin-positive epithelial cells are a small population of quiescent gastric progenitor cells. We expressed PPARD from a villin promoter to investigate the role of these cells and PPARD in development of gastric cancer. METHODS: We analyzed gastric tissues from mice that express the Ppard (PPARD1 and PPARD2 mice) from a villin promoter, and mice that did not carry this transgene (controls), by histology and immunohistochemistry. We performed cell lineage-tracing experiments and analyzed the microbiomes, chemokine and cytokine production, and immune cells and transcriptomes of stomachs of these mice. We also performed immunohistochemical analysis of PPARD levels in 2 sets of human gastric tissue microarrays. RESULTS: Thirty-eight percent of PPARD mice developed spontaneous, invasive gastric adenocarcinomas, with severe chronic inflammation. Levels of PPARD were increased in human gastric cancer tissues, compared with nontumor tissues, and associated with gastric cancer stage and grade. We found an inverse correlation between level of PPARD in tumor tissue and patient survival time. Gastric microbiomes from PPARD and control mice did not differ significantly. Lineage-tracing experiments identified villin-expressing gastric progenitor cells (VGPCs) as the origin of gastric tumors in PPARD mice. In these mice, PPARD up-regulated CCL20 and CXCL1, which increased infiltration of the gastric mucosa by immune cells. Immune cell production of inflammatory cytokines promoted chronic gastric inflammation and expansion and transformation of VGPCs, leading to tumorigenesis. We identified a positive-feedback loop between PPARD and interferon gamma signaling that sustained gastric inflammation to induce VGPC transformation and gastric carcinogenesis. CONCLUSIONS: We found PPARD overexpression in VPGCs to result in inflammation, dysplasia, and tumor formation. PPARD and VGPCs might be therapeutic targets for stomach cancer.
BACKGROUND & AIMS: The peroxisome proliferator-activated receptor delta (PPARD) regulates cell metabolism, proliferation, and inflammation and has been associated with gastric and other cancers. Villin-positive epithelial cells are a small population of quiescent gastric progenitor cells. We expressed PPARD from a villin promoter to investigate the role of these cells and PPARD in development of gastric cancer. METHODS: We analyzed gastric tissues from mice that express the Ppard (PPARD1 and PPARD2 mice) from a villin promoter, and mice that did not carry this transgene (controls), by histology and immunohistochemistry. We performed cell lineage-tracing experiments and analyzed the microbiomes, chemokine and cytokine production, and immune cells and transcriptomes of stomachs of these mice. We also performed immunohistochemical analysis of PPARD levels in 2 sets of human gastric tissue microarrays. RESULTS: Thirty-eight percent of PPARDmice developed spontaneous, invasive gastric adenocarcinomas, with severe chronic inflammation. Levels of PPARD were increased in humangastric cancer tissues, compared with nontumor tissues, and associated with gastric cancer stage and grade. We found an inverse correlation between level of PPARD in tumor tissue and patient survival time. Gastric microbiomes from PPARD and control mice did not differ significantly. Lineage-tracing experiments identified villin-expressing gastric progenitor cells (VGPCs) as the origin of gastric tumors in PPARDmice. In these mice, PPARD up-regulated CCL20 and CXCL1, which increased infiltration of the gastric mucosa by immune cells. Immune cell production of inflammatory cytokines promoted chronic gastric inflammation and expansion and transformation of VGPCs, leading to tumorigenesis. We identified a positive-feedback loop between PPARD and interferon gamma signaling that sustained gastric inflammation to induce VGPC transformation and gastric carcinogenesis. CONCLUSIONS: We found PPARD overexpression in VPGCs to result in inflammation, dysplasia, and tumor formation. PPARD and VGPCs might be therapeutic targets for stomach cancer.
Authors: James R Goldenring; Ki Taek Nam; Timothy C Wang; Jason C Mills; Nicholas A Wright Journal: Gastroenterology Date: 2010-05-05 Impact factor: 22.682
Authors: Dingzhi Wang; Lingchen Fu; Wei Ning; Lixia Guo; Xiaofei Sun; Sudhansu K Dey; Rupesh Chaturvedi; Keith T Wilson; Raymond N DuBois Journal: Proc Natl Acad Sci U S A Date: 2014-04-24 Impact factor: 11.205
Authors: Yoku Hayakawa; Guangchun Jin; Hongshan Wang; Xiaowei Chen; Christoph B Westphalen; Samuel Asfaha; Bernhard W Renz; Hiroshi Ariyama; Zinaida A Dubeykovskaya; Yoshihiro Takemoto; Yoomi Lee; Ashlesha Muley; Yagnesh Tailor; Duan Chen; Sureshkumar Muthupalani; James G Fox; Arthur Shulkes; Daniel L Worthley; Shigeo Takaishi; Timothy C Wang Journal: Gut Date: 2014-06-20 Impact factor: 23.059
Authors: Yoku Hayakawa; Hiroshi Ariyama; Jitka Stancikova; Kosuke Sakitani; Samuel Asfaha; Bernhard W Renz; Zinaida A Dubeykovskaya; Wataru Shibata; Hongshan Wang; Christoph B Westphalen; Xiaowei Chen; Yoshihiro Takemoto; Woosook Kim; Shradha S Khurana; Yagnesh Tailor; Karan Nagar; Hiroyuki Tomita; Akira Hara; Antonia R Sepulveda; Wanda Setlik; Michael D Gershon; Subhrajit Saha; Lei Ding; Zeli Shen; James G Fox; Richard A Friedman; Stephen F Konieczny; Daniel L Worthley; Vladimir Korinek; Timothy C Wang Journal: Cancer Cell Date: 2015-11-12 Impact factor: 31.743
Authors: Shivanand Pudakalakatti; Mark Titus; José S Enriquez; Sumankalai Ramachandran; Niki M Zacharias; Imad Shureiqi; Yi Liu; James C Yao; Xiangsheng Zuo; Pratip K Bhattacharya Journal: Int J Mol Sci Date: 2022-01-31 Impact factor: 6.208